Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | GMNN | O75496 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25099265 | 1.00 | LMNA (0.66) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL12152164 | 1.00 | LMNA (0.66) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| Bromide SCHEMBL2995962 | 0.98 | LMNA (0.64) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| Hydrochloric Acid SCHEMBL8752462 | 0.98 | LMNA (0.69) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL27777262 | 0.89 | LMNA (0.62) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| Butyryl-Carnitine SCHEMBL25274079 | 0.88 | CYP1A2 (0.68) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL20530318 | 0.87 | LMNA (0.64) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL20530359 | 0.87 | LMNA (0.64) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL27768779 | 0.85 | LMNA (0.66) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL27925466 | 0.85 | LMNA (0.66) | LMNASMN1; SMN2CYP1A2MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118759203-B | Lipid biomarker for wild and cultured bighead carp and application thereof | 中国水产科学研究院长江水产研究所 | 2025-03-11 | — | — | CN | claimed |
| CN-118961905-A | Craniopharyngeoma serum metabolite spectrum, intestinal flora spectrum and application thereof | 复旦大学附属华山医院 | 2024-11-15 | — | — | CN | claimed |
| CN-118759203-A | Lipid biomarker for wild and cultured bighead carp and application thereof | 中国水产科学研究院长江水产研究所 | 2024-10-11 | — | — | CN | claimed |
| CN-116298235-A | Serum metabolism biomarker for diagnosing or monitoring breast cancer and screening method thereof | 哈尔滨医科大学 | 2023-06-23 | — | — | CN | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| CN-108627647-A | A kind of detection of posttranslational modification proteomics and quantitative approach | 四川大学 | 2018-10-09 | — | — | CN | claimed |
| CN-101616665-B | Composition useful for the treatment of type 2 diabetes | SIGMA TAU IND FARMACEUTI IT | 2013-03-27 | — | — | CN | claimed |
| US-20250306042-A1 | METHOD FOR DIAGNOSING ENDOMETRIOSIS IN A SUBJECT | UNIV LJUBLJANI (SI) | 2025-10-02 | — | — | US | disclosed |
| US-12329726-B2 | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-06-17 | — | — | US | disclosed |
| CN-118759203-B | Lipid biomarker for wild and cultured bighead carp and application thereof | 中国水产科学研究院长江水产研究所 | 2025-03-11 | — | — | CN | disclosed |
| CN-118759203-B | Lipid biomarker for wild and cultured bighead carp and application thereof | 中国水产科学研究院长江水产研究所 | 2025-03-11 | — | — | CN | disclosed |
| CN-118961905-A | Craniopharyngeoma serum metabolite spectrum, intestinal flora spectrum and application thereof | 复旦大学附属华山医院 | 2024-11-15 | — | — | CN | disclosed |
| CN-118759203-A | Lipid biomarker for wild and cultured bighead carp and application thereof | 中国水产科学研究院长江水产研究所 | 2024-10-11 | — | — | CN | disclosed |
| US-8067468-B2 | L-carnitine and alkanoyl L-carnitine phytates and process for preparing the same | SCIAN LABORATORIES, LLC | 2011-11-29 | — | — | US | disclosed |
| US-8049038-B2 | Carnitine conjugates of adamantanamines derivatives as dual prodrugs for various uses | SSV THERAPEUTICS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110212166-A1 | CARNITINE CONJUGATES OF ADAMANTANAMINES DERIVATIVES AS DUAL PRODRUGS FOR VARIOUS USES | SSV THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7977511-B2 | Carnitine conjugates of adamantanamines and neramexane derivatives as dual prodrugs for various uses | SSV THERAPEUTICS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100317890-A1 | L-carnitine and alkanoyl L-carnitine phytates and process for preparing the same | SCIAN LABORATORIES, LLC (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010005465-A1 | L-CARNITINE AND ALKANOYL L-CARNITINE PHYTATES AND PROCESS FOR PREPARING THE SAME | SCIAN LABORATORIES, LLC (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20090246267-A1 | Carnitine Conjugates of Adamantanamines and Neramexane Derivatives as Dual Prodrugs for Various Uses | SSV THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246267-A1 | Carnitine Conjugates of Adamantanamines and Neramexane Derivatives as Dual Prodrugs for Various Uses | COASY, SLC5A7, CRAT | LMNA 1306/4885SMN1; SMN2 1213/4885CYP1A2 432/4885 |
| US-20100317890-A1 | L-carnitine and alkanoyl L-carnitine phytates and process for preparing the same | CPT1A, CPT1B, SLC25A20 | LMNA 212/4885SMN1; SMN2 927/4885CYP1A2 2417/4885 |
| US-20110212166-A1 | CARNITINE CONJUGATES OF ADAMANTANAMINES DERIVATIVES AS DUAL PRODRUGS FOR VARIOUS USES | CRAT, COASY, CPT1A | LMNA 1325/4885SMN1; SMN2 952/4885CYP1A2 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.